Chugai Launches Pumozyme In Japan
This article was originally published in PharmAsia News
Chugai Pharmaceuticals began sales of cystic fibrosis treatment Pulmozyme (dornase) in Japan on June 8.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.